STVN
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Article Summary
HOLD- Stevanato Group S.p.A. (NYSE: STVN) announced that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT) Stevanato Group Spa is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.
- The company will host a conference call and webcast at 8:30am ET on August 4 to discuss financial results.
- Management will refer to a slide presentation available on the morning of the call on the Financial Results page.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 15.5% | 25% | 60.0 ptsModerate (15.5%) - Decent growth |
| EPS Growth Next 5Y ? | 16.9% | 25% | 50.0 ptsMeets Minimum (16.9%) - Passes screener |
| Target Price Upside ? | 26.1% | 20% | 75.0 ptsSignificant Upside (26.1%) - Target: $24.24 vs Current: $19.23 |
| Gross Margin % ? | 28.1% | 15% | 40.0 ptsModerate (28.1%) - Adequate margins |
| Drawdown from 52-Wk High ? | -31.3% | 15% | 80.0 ptsSolid Dip (-31.3%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About STVN
- Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
- It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
- The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services.
- It also provides contract development and manufacturing services for customer-owned drug delivery devices.
- The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers.
- The company was founded in 1949 and is headquartered in Piombino Dese, Italy.
- Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.